ADAPTIVE BIOTECHNOLOGIES CORPORATION Financing Cash Flow
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Financing Cash Flow of $149.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $142.19M, a 8731.55% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $7.50M, a 37.59% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $21.66M, a 16953.54% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.68M, a 4110.00% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for fiscal 2025 was $30.40M, a 12515.35% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for fiscal 2024 was $241.00K, a 89.27% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for fiscal 2023 was $2.25M, a 98.30% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) financing activities for fiscal 2022 was $132.26M, a 387.24% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $149.69M 10-Q · filed 2026-08-04 | $171.35M derived: sum of 3 quarters · filed 2026-08-04 | $173.03M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.50M 10-Q · filed 2026-05-05 | $29.16M derived: sum of 2 quarters · filed 2026-05-05 | $30.84M derived: sum of 3 quarters · filed 2026-05-05 | $32.45M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $21.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.34M derived: sum of 2 quarters · filed 2026-02-26 | $24.95M derived: sum of 3 quarters · filed 2026-08-04 | $30.40M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.29M derived: sum of 2 quarters · filed 2026-08-04 | $8.74M 10-Q · filed 2025-11-05 | $8.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.06M 10-Q · filed 2026-08-04 | $7.19M derived: sum of 3 quarters · filed 2026-08-04 | $7.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $5.45M 10-Q · filed 2026-05-05 | $5.58M derived: sum of 2 quarters · filed 2026-05-05 | $5.62M derived: sum of 3 quarters · filed 2026-05-05 | $5.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $167.00K derived: sum of 2 quarters · filed 2026-02-26 | $197.00K derived: sum of 3 quarters · filed 2026-02-26 | $241.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $70.00K derived: sum of 2 quarters · filed 2025-11-05 | $114.00K 10-Q · filed 2025-11-05 | $201.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $74.00K 10-Q · filed 2025-08-05 | $161.00K derived: sum of 3 quarters · filed 2026-02-26 | $178.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $44.00K 10-Q · filed 2025-05-01 | $131.00K derived: sum of 2 quarters · filed 2026-02-26 | $148.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $104.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.57M derived: sum of 3 quarters · filed 2026-02-26 | $2.25M 10-K · filed 2026-02-26 |
| 2023-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.49M derived: sum of 2 quarters · filed 2024-11-07 | $2.16M 10-Q · filed 2024-11-07 | $2.16M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.14M 10-Q · filed 2024-08-01 | $2.15M derived: sum of 3 quarters · filed 2025-03-03 | $127.67M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $672.00K 10-Q · filed 2024-05-07 | $678.00K derived: sum of 2 quarters · filed 2025-03-03 | $126.20M derived: sum of 3 quarters · filed 2025-03-03 | $130.19M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $125.53M derived: sum of 2 quarters · filed 2025-03-03 | $129.52M derived: sum of 3 quarters · filed 2025-03-03 | $132.26M 10-K · filed 2025-03-03 |
| 2022-09-30 | $125.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $129.51M derived: sum of 2 quarters · filed 2023-11-09 | $132.26M 10-Q · filed 2023-11-09 | $135.54M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $6.74M 10-Q · filed 2023-08-02 | $10.02M derived: sum of 3 quarters · filed 2024-02-29 | $12.94M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.75M 10-Q · filed 2023-05-03 | $6.03M derived: sum of 2 quarters · filed 2024-02-29 | $8.95M derived: sum of 3 quarters · filed 2024-02-29 | $15.28M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.20M derived: sum of 2 quarters · filed 2024-02-29 | $12.53M derived: sum of 3 quarters · filed 2024-02-29 | $27.15M 10-K · filed 2024-02-29 |
| 2021-09-30 | $2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $9.25M derived: sum of 2 quarters · filed 2022-11-03 | $23.87M 10-Q · filed 2022-11-03 | $30.12M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $6.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $20.94M 10-Q · filed 2022-08-03 | $27.20M derived: sum of 3 quarters · filed 2023-02-14 | $303.23M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $14.61M 10-Q · filed 2022-05-04 | $20.87M derived: sum of 2 quarters · filed 2023-02-14 | $296.90M derived: sum of 3 quarters · filed 2023-02-14 | $303.24M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $282.29M derived: sum of 2 quarters · filed 2023-02-14 | $288.63M derived: sum of 3 quarters · filed 2023-02-14 | $293.59M 10-K · filed 2023-02-14 |
| 2020-09-30 | $276.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $282.38M derived: sum of 2 quarters · filed 2021-11-03 | $287.33M 10-Q · filed 2021-11-03 | $289.08M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $6.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $11.30M 10-Q · filed 2021-08-04 | $13.04M derived: sum of 3 quarters · filed 2022-02-15 | $332.59M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $4.96M 10-Q · filed 2021-05-05 | $6.71M derived: sum of 2 quarters · filed 2022-02-15 | $326.25M derived: sum of 3 quarters · filed 2022-02-15 | $324.75M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $321.30M derived: sum of 2 quarters · filed 2022-02-15 | $319.79M derived: sum of 3 quarters · filed 2022-02-15 | $319.92M 10-K · filed 2022-02-15 |
| 2019-09-30 | $319.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $318.05M derived: sum of 2 quarters · filed 2020-11-10 | $318.17M 10-Q · filed 2020-11-10 | $318.45M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$1.38M 10-Q · filed 2020-08-10 | -$1.10M derived: sum of 3 quarters · filed 2021-02-24 | -$1.04M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $124.00K 10-Q · filed 2020-05-12 | $402.00K derived: sum of 2 quarters · filed 2021-02-24 | $459.00K derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $335.00K derived: sum of 2 quarters · filed 2021-02-24 | $1.25M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $970.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $913.00K 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | $50.03M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |